21 CFR Part 54 (Financial Disclosure by Clinical Investigators)

21 CFR Part 54 is the FDA regulation that requires sponsors to identify, and FDA to evaluate, financial interests and arrangements held by the clinical investigators on a study FDA relies on to review a marketing application. It exists to address a specific bias risk: an investigator with equity in the sponsor, a royalty or proprietary interest in the product, or compensation tied to the study’s outcome may — even unintentionally — influence how a study is conducted, reported, or interpreted. Part 54 does not prohibit these financial relationships; it requires them to be surfaced so FDA can weigh their potential effect on the reliability of the data before relying on the study.

Scope: which studies Part 54 reaches

Under 21 CFR 54.1 and 54.3, Part 54 applies to any covered clinical study — defined at 21 CFR 54.2(e) as a study in humans submitted to FDA in support of a marketing application (an NDA, ANDA, or BLA reviewed by CDER/CBER, or a PMA or certain 510(k) submissions reviewed by CDRH) that the applicant or FDA relies on to establish effectiveness, including a study intended to show equivalence to an approved product, or a study in which a single investigator makes a significant contribution to the demonstration of safety. A study that is never submitted as evidentiary support in a marketing application — for example, an exploratory early-phase study used only to guide internal development decisions — falls outside Part 54’s disclosure requirement, even if the same investigators and product are involved.

What sponsors must obtain and submit

For every covered clinical study, the sponsor of the marketing application must obtain financial disclosure information covering each listed or principal investigator, every subinvestigator who took part, and each one’s spouse and dependent children. Under 21 CFR 54.2 and 54.4, the interests screened for include compensation structured to depend on study outcome, a significant equity interest in the sponsor (over $50,000 for a publicly traded sponsor, per 21 CFR 54.2(b)), a proprietary interest in the tested product (patent, trademark, copyright, or license), and other significant payments from the sponsor totaling more than $25,000 during the disclosure period (21 CFR 54.2(f)). The sponsor then files exactly one of two forms with the application: FDA Form 3454 if the review finds no covered investigator has a disclosable interest, or FDA Form 3455 to disclose the specific interest, its value, and any steps taken to limit its potential to bias the study, where one does exist. See the FDA Form 3454 entry for the full mechanics of that certification/disclosure split — this page focuses on the parent regulation’s scope and on the two provisions the forms themselves don’t cover: FDA’s evaluation authority and the sponsor’s recordkeeping duty.

What FDA does with the disclosure: 21 CFR 54.5

Financial disclosure under Part 54 is not a paperwork formality FDA files away unread — 21 CFR 54.5 gives FDA explicit authority to act on what it learns. FDA evaluates the impact of any disclosed financial interest on the reliability of the study, weighing both the size and nature of the interest and whatever bias-mitigating study design features are present — multiple investigators (most without a disclosable interest), blinding, and objective endpoints are cited in the regulation as design choices that can adequately guard against bias even where a financial interest exists. Where a disclosed interest still raises a serious question about the integrity of the data, FDA may: initiate its own audit of the data from that investigator; request that the applicant submit further analyses of the data to assess how that investigator’s results affected the study’s overall outcome; request that the applicant conduct additional independent studies to confirm the results; or refuse to treat the covered clinical study as providing data that can support an FDA action on the application. In practice, this gives Part 54 real regulatory teeth: an undisclosed or unmitigated financial interest can put an entire pivotal study’s evidentiary weight at risk.

Recordkeeping: 21 CFR 54.6

Applicants who submit a marketing application containing a covered clinical study must retain complete records of the financial interests and arrangements covered by Part 54 — for investigators who are not full-time or part-time employees of the sponsor — for two years after the date the application is approved. FDA officers may request access to, and copy and verify, these records at reasonable times. This retention obligation sits alongside, and outlasts, the point-in-time certification or disclosure made on Form 3454 or 3455 at filing; it is what lets FDA revisit the underlying financial-interest documentation later if a question arises during or after review.

How Part 54 relates to other investigator paperwork

Part 54 addresses a different question, at a different point in the trial lifecycle, than the paperwork investigators sign at trial start-up. FDA Form 1572 (Statement of Investigator) is signed per-investigator when a trial opens under an IND, and commits the investigator to conducting the study per the protocol and complying with FDA’s human-subjects regulations (21 CFR Part 50) and IRB-oversight regulations (21 CFR Part 56). Part 54’s certification or disclosure comes later, at marketing-application stage, and asks a financial rather than procedural question: did any of those same investigators have a financial stake that could color the results FDA is now being asked to rely on. The two obligations are complementary and independently required — neither substitutes for the other.

Related CASRAI terms

• FDA Form 3454 (Certification: Financial Interests and Arrangements of Clinical Investigators) — the certification form filed under Part 54 when no covered investigator has a disclosable interest; its counterpart Form 3455 is used when one exists.
• FDA Form 1572 (Statement of Investigator) — the separate, earlier investigator commitment signed at trial start-up under an IND.
• 21 CFR Part 50 (Protection of Human Subjects) — FDA’s informed-consent regulation, a distinct requirement Form 1572 also commits investigators to.
• 21 CFR Part 56 (Institutional Review Boards) — FDA’s IRB-oversight regulation, working alongside Part 50 the way Part 54 works alongside both.
• Conflict of Interest (COI) in Research — the broader research-integrity concept Part 54’s investigator financial-disclosure requirement is one regulated instance of.